• Prajyot Dipak Manjramkar
• Mande Sandip Padmakar
• Maknikar Sakshi Namdevrao
• Arati Kishanrao Landge
• Kshirsagar Varsha Rudrappa

Migraine is a common neurological illness with frequent episodes of headache, usually of moderate to severe intensity, frequently preceded or accompanied by nausea, vomiting, and sensitivity to light and sound. Drug treatments like triptans, nonsteroidal anti-inflammatory drugs (NSAIDs), calcitonin gene-related peptide (CGRP) inhibitors, beta-blockers, and anticonvulsants are generally prescribed for the treatment of both acute and prophylactic stages. Yet, prolonged application of such treatments involves serious risks of adverse drug reactions (ADRs) from mild gastrointestinal side effects up to severe cardiovascular and neuropsychiatric complications. Pharmacovigilance is essential to maintain drug safety by detection, observation, and assessment of ADRs induced by migraine medications. The pharmacovigilance situation with migraine treatment is discussed in this review, emphasizing the most commonly detected ADRs, post-marketing surveillance information, and regulatory actions. Particular focus is placed on new migraine therapies, including CGRP inhibitors, with enhanced efficacy but novel safety issues. The contributions of spontaneous reporting systems, electronic health records, and patient-reported outcomes to ADR detection are also highlighted. Enhancing pharmacovigilance can enhance therapeutic success, minimize medication-related harm, and inform regulatory policy for safer migraine treatment. Future studies must be based on real-world evidence and individualized medicine strategies to maximize drug safety in migraine treatment.

Pharmacovigilance, Migraine, Adverse Drug Reactions, Triptans, CGRP Inhibitors, Drug Safety, Post-Marketing Surveillance

"PHARMACOVIGILANCE IN MIGRAINE TREATMENT: ASSESSING ADRS AND PATIENT SAFETY", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.12, Issue 3, page no.i769-i776, March-2025, Available :http://www.jetir.org/papers/JETIR2503900.pdf

"PHARMACOVIGILANCE IN MIGRAINE TREATMENT: ASSESSING ADRS AND PATIENT SAFETY", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.12, Issue 3, page no. ppi769-i776, March-2025, Available at : http://www.jetir.org/papers/JETIR2503900.pdf